How do airplanes fly? An aerospace engineer explains the physics of flight 
Could a telescope ever see the beginning of time? An astronomer explains 
Tatahouine: 'Star Wars meteorite' sheds light on the early Solar System 
The brightest object in the universe is a black hole that eats a star a day 
Genetic diseases: How scientists are working to make DNA repair (almost) a piece of cake 
Why some people don't trust science – and how to change their minds 
Larger and more frequent solar storms will make for potential disruptions and spectacular auroras on Earth 
Why is the universe ripping itself apart? A new study of exploding stars shows dark energy may be more complicated than we thought 
The brain is the most complicated object in the universe. This is the story of scientists’ quest to decode it – and read people’s minds 
Spacesuits need a major upgrade for the next phase of exploration 
Six space missions to look forward to in 2024 
Archeoastronomy uses the rare times and places of previous total solar eclipses to help us measure history 
The mystery of consciousness shows there may be a limit to what science alone can achieve 
If life exists on Jupiter’s moon Europa, scientists might soon be able to detect it 
Orbital resonance − the striking gravitational dance done by planets with aligning orbits 
Dark energy is one of the biggest puzzles in science and we're now a step closer to understanding it 
Scientists around the world have various ways to tackle the search for finding a cure for cancer. While that remains one of the biggest challenges in medical science, researchers are also making huge efforts to develop better immunotherapies and more effective cancer drugs. This month, different groups of researchers have made significant developments that could each pave the way to better treatment strategies for patients battling cancers of the breast, pancreas, and prostate.
Researchers from Duke Cancer Institute in Durham, North Carolina recently published their findings in the journal Nature Communications (via Medical Xpress) on how the immune system can better identify breast cancer cells. In a pre-clinical trial on a mouse, the scientists were reportedly able to attack the enzyme cells that help in the spread of breast cancer. As a result, the immune system’s T-cells can properly identify the tumors and tackle it.
This can then greatly help in making immunotherapies work much better for many patients. "We found that inhibition of the activity of this enzyme decreased the ability of macrophages in tumors to suppress an immune attack on cancer cells and indeed encouraged them to start producing chemicals that attract more cancer-killing T cells into the tumor," Dr. Donald McDonnell of Duke's Department of Pharmacology & Cancer Biology explained.
Dr. Brian Boone, a surgical oncologist and assistant professor at West Virginia University’s School of Medicine, explained that pancreatic cancer tumors are usually difficult to be surgically removed. In a study published in the Journal of the National Cancer Institute (via EurekAlert), they shared a development they observed in using the cancer drug FOLFIRINOX that increases the survivability among pancreatic cancer patients.
Boone’s team observed 313 pancreatic cancer patients taking FOLFIRINOX with tumors that cannot be removed by surgery because it is located too close to a blood vessel. The researchers found that the drug either increases the patients’ survival rate or shrinks the tumors over a certain period making surgery a possible treatment option. "There's no control group, but when you compare it to what we've historically seen in patients that are borderline resectable and that we take straight to surgery, FOLFIRINOX resulted in better survival and better rates of resection," Boone explained
